HLA-G and neoplasm: Despite that immunogenic tumours are susceptible to ICI therapies (3, 26), different immune evasion mechanisms such as HLA-I downmodulation, mutations in β2-microglobulin, loss-of-function mutations in JAK1/2, or WNT signalling activation can lead to acquired resistance to ICIs (27).